Regeneron Pharmaceuticals Inc REGN

What the company does

Regeneron Pharmaceuticals Inc is a large-cap company in the Healthcare sector (Biotechnology), with a market value of $82.9B, based in the USA.

It employs about 15,410 people and has been listed since Apr 02, 1991.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.

Cheap or expensive? relatively cheap

Its price-to-earnings (P/E) is 19.9 versus 36.9 for the median of the Healthcare sector in our universe (25 companies) — relatively cheap.

Revenue is growing 17% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 14.1 — they expect higher earnings.

The average analyst price target is 867.33, 8% above the current price (their view, not ours).

The stock sits at 81% of its one-year range (0% = the low, 100% = the high).

The risks

• • Quarterly report in 5 days (2026-10-30) — a day the stock can move a lot.

Strengths

• ✅ Profitable — 30 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Buys back its shares (2% fewer shares in a year).
• ✅ More cash than debt.
• ✅ Most analysts rate it buy (19 vs 1).
• ✅ Revenue is growing 17% a year.
• ✅ Pays a dividend (0.4% a year).

What changed this week

Over the past week the stock rose 1.8% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

This week's news

• 1 safe-and-steady stock with exciting potential and 2 facing headwinds finance.yahoo.com · 2026-10-23
  What the article says

  1 safe-and-steady stock with exciting potential and 2 facing headwinds A stock with low volatility can be reassuring, but it doesn't always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. Finding the right balance between safety and returns… source ↗

• Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release finance.yahoo.com · 2026-10-23
  What the article says

  The market expects Regeneron (REGN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term… source ↗

• Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions? finance.yahoo.com · 2026-10-22
  What the article says

  Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics - US's Substack. In this article, we will summarize the bulls' thesis on GILD. Gilead Sciences, Inc.'s share was trading at $156.51 as of October 20th 2026. GILD's trailing and forward P/E were 17.84 and 15.55… source ↗

• Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results finance.yahoo.com · 2026-10-19
  What the article says

  Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its "Partners Fund". The letter can be downloaded here. Coming into this year, the Fund's three-year annualized returns were at 11.7%, but recent performance, particularly this year and in Q3, has raised… source ↗

• Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher? finance.yahoo.com · 2026-10-19
  What the article says

  Kodiak Sciences KOD could unlock significant growth opportunities through Zenkuda (tarcocimab tedromer), its late-stage investigational therapy for retinal diseases. Positive phase III results across wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and retinal vein occlusion (RVO) strengthened… source ↗

• Sensorion Announces the Appointment of Peter Weber, MD, MBA, as Chief Medical Officer finance.yahoo.com · 2026-10-19
  What the article says

  Dr. Weber, an otologist and neurotologist who led the clinical development of the first FDA-approved gene therapy for genetic hearing loss, joins as SENS-601 advances into the clinic MONTPELLIER, France & CAMBRIDGE, Mass., October 19, 2026--(BUSINESS WIRE)--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the… source ↗

What changed since last week

No material change: same valuation verdict, same risk flags, price moved less than 3%.